Kai Helge Schmidt,Joana Adler,Olympia Bikou et al.
Kai Helge Schmidt et al.
Left heart disease (LHD) is the most common cause of pulmonary hypertension (PH), which is further categorised into isolated post-capillary PH (IpcPH) and combined pre- and post-capillary PH (CpcPH).With the aim of developing treatment stra...
Ekkehard Grünig,Katrin Milger,Albert Omlor et al.
Ekkehard Grünig et al.
Targeted therapy for pulmonary arterial hypertension has a positive impact on the symptoms and prognosis of the disease. Targeted and early combination therapy demonstrates greater improvements compared to monotherapy. For treatment decisio...
Mona Lichtblau,Satenik Harutyunova,Hans Klose et al.
Mona Lichtblau et al.
General measures and special conditions were addressed by the ninth task force at the 7th World Symposium on Pulmonary Hypertension. It focused primarily on the patient perspective, general and supportive measures, and challenging patient c...
[Risk Stratification and Treatment Goals for Pulmonary Arterial Hypertension] [0.03%]
[肺动脉高压的风险分层与治疗目标]
Horst Olschewski,Michaela Barnikel,David Pittrow et al.
Horst Olschewski et al.
Risk stratification plays an important role in predicting outcomes and guiding treatment decisions of patients with pulmonary arterial hypertension (PAH). The three most important non-invasive predictive prognostic factors are the World Hea...
Elena Pfeuffer-Jovic,Kai Helge Schmidt,Teresa John et al.
Elena Pfeuffer-Jovic et al.
Pulmonary hypertension (PH) is a complex and heterogeneous disease, which complicates its precise classification, diagnosis, and treatment. Established approaches for assessing PH include echocardiography, lung scintigraphy, and cross-secti...
Elena Pfeuffer-Jovic,Kai Helge Schmidt,Teresa John et al.
Elena Pfeuffer-Jovic et al.
For the diagnosis of pulmonary hypertension (PH), a stepwise diagnostic algorithm is recommended to identify patients who require referral to a PH center and who require invasive hemodynamic assessment. In cases of high probability of pulmo...
Philipp Douschan,Ann-Sophie Kaemmerer-Suleiman,Benjamin Egenlauf et al.
Philipp Douschan et al.
Pulmonary Hypertension (PH) is characterized as a hemodynamic disorder defined by a mean pulmonary arterial pressure (mPAP) exceeding 20 mmHg at rest. Classification into distinct subtypes is guided by measurements of pulmonary arterial wed...
[Pathophysiology of the Right Ventricle and its Pulmonary Vascular Interaction] [0.03%]
右心室与肺血管相互作用的病理生理学
Khodr Tello,Nils Kremer,Andreas J Rieth et al.
Khodr Tello et al.
Authored by a consortium of experts from the German-speaking countries, this commentary on the 2024 World Symposium on Pulmonary Hypertension (WSPH) statement spotlights the updated definition of right-heart failure and its quantification t...
Christina A Eichstaedt,Andrea Olschewski,Lars Harbaum et al.
Christina A Eichstaedt et al.
Genetics and pathobiology were addressed at the 7th World Symposium on Pulmonary Hypertension in Task Forces 2 and 3. The Genetics Task Force also focused on precision medicine approaches, and the Pathobiology working group concentrated hea...
[Innovations in the Field of Pulmonary Hypertension - Critical Assessment of the Results of the 7th World Symposium on Pulmonary Hypertension] [0.03%]
肺动脉高压领域创新研究——第7届世界肺动脉高压大会成果评介
Ekkehard Grünig,Christina A Eichstaedt,Nicola Benjamin
Ekkehard Grünig
This special issue summarizes, comments, and discusses the topics developed by the task forces at the 7th World Symposium on Pulmonary Hypertension in Barcelona in 2024 in consideration of recent literature. Particular attention is paid to ...